SubjectWell Welcomes Matthias Roos as Scientific Affairs Director

SubjectWell Announces New Leadership in Scientific Affairs

SubjectWell is excited to share the news of Matthias Roos's appointment as the new Director of Scientific Affairs. As a company dedicated to enhancing patient recruitment and addressing challenges in clinical development, this addition marks a significant step forward.

Matthias Roos: An Asset to SubjectWell

Matthias Roos will spearhead global research initiatives and lead thought leadership programs tailored to the needs of sponsors, clinical research organizations (CROs), and clinical sites. With a robust background in clinical trial technology, consulting, and strategic leadership, he brings invaluable expertise that positions SubjectWell to tackle the complexities of clinical development.

A Warm Welcome from Leadership

"We're thrilled to welcome Matthias Roos to the SubjectWell team," expressed Fred Martin, CEO of SubjectWell. "His deep understanding of scientific, business, clinical, and regulatory complexities strengthens our ability to transform the industry's approach to clinical development, patient recruitment, and the patient experience."

Extensive Experience in Healthcare and Technology

Matthias's background encompasses healthcare, pharmaceuticals, and clinical trial technology. Before joining SubjectWell, he served as Director of Strategy and trained with Climedo, focusing on launch excellence and innovative solutions for Real-World Evidence and non-interventional studies. His previous role as a Senior Consultant for McKinsey & Company allowed him to assist major clients in refining corporate strategy and optimizing operations.

Academic Achievements and Publications

Matthias Roos holds a Ph.D. in Physics from The Martin Luther University of Halle-Wittenberg and completed research as a Postdoctoral Fellow at the Massachusetts Institute of Technology (MIT). His academic contributions include five peer-reviewed publications. His remarkable achievements have been recognized with prestigious honors, such as the Ernst Award from the German Chemical Society, solidifying his reputation in the field. Over his career, he has authored 15 scientific papers with over 600 citations, showcasing his commitment to knowledge advancement.

About SubjectWell

SubjectWell leads the charge in revolutionizing patient recruitment. The company enhances the experience for sponsors, CROs, and sites through a robust and patient-focused technology platform. With a growing Patient Network of over 13 million patients, SubjectWell offers multilingual patient and site companions, extensive recruiting capabilities in over 102 countries, and an expansive digital media network. These cutting-edge solutions aim to reduce site burden and elevate the patient experience, addressing pressing challenges in patient recruitment.

Media Contacts

For inquiries, please contact the Interdependence Public Relations team: Haylee Elmore and Alysha Eipperle at 602-350-1455.

Frequently Asked Questions

Who is Matthias Roos?

Matthias Roos is the newly appointed Director of Scientific Affairs at SubjectWell, focusing on enhancing patient recruitment strategies.

What is SubjectWell known for?

SubjectWell is known for transforming patient recruitment in clinical development through innovative technology and patient-centered solutions.

What experience does Matthias bring to SubjectWell?

Matthias brings extensive experience from his previous roles in healthcare and clinical trial technology, including leadership in strategy development.

What awards has Matthias Roos received?

Matthias received the Ernst Award from the German Chemical Society and has published numerous scientific papers throughout his career.

How does SubjectWell support clinical trials?

SubjectWell supports clinical trials by providing a comprehensive platform that streamlines recruitment and enhances the patient experience across various study types.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.